|
[1] ZHOU F,ZHOU J,WANG W,et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018:A systematic review and meta-analysis[J]. Hepatology,2019,70(4):1119-1133.
|
|
[2] SLIJEPCEVIC D,van de GRAAF SF. Bile acid uptake transporters as targets for therapy[J]. Dig Dis,2017,35(3):251-258.
|
|
[3] YANG ZX,SHEN W,SUN H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease[J]. Hepatol Int,2010,4(4):741-748.
|
|
[4] BECHMANN LP,KOCABAYOGLU P,SOWA JP,et al. Free fatty acids repress small heterodimer partner(SHP)activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis[J].Hepatology,2013,57(4):1394-1406.
|
|
[5] PURI P,DAITA K,JOYCE A,et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids[J]. Hepatology,2018,67(2):534-548.
|
|
[6] TANG Y,ZHANG J,LI J,et al. Turnover of bile acids in liver,serum and caecal content by high-fat diet feeding affects hepatic steatosis in rats[J]. Biochim Biophys Acta Mol Cell Biol Lipids,2019,1864(10):1293-1304.
|
|
[7] SUGA T,YAMAGUCHI H,OGURA J,et al. Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis[J]. Toxicol Appl Pharmacol,2019,379:114664.
|
|
[8] ARAB JP,KARPEN SJ,DAWSON PA,et al. Bile acids and nonalcoholic fatty liver disease:Molecular insights and therapeutic perspectives[J]. Hepatology,2017,65(1):350-362.
|
|
[9] PREIDIS GA,KIM KH,MOORE DD. Nutrient-sensing nuclear receptors PPARαand FXR control liver energy balance[J]. J Clin Invest,2017,127(4):1193-1201.
|
|
[10] VELAZQEZ-VILLEGAS LA,PERINO A,LEMOS V,et al. TGR5signalling promotes mitochondrial fission and beige remodelling of white adipose tissue[J]. Nat Commun,2018,9(1):245.
|
|
[11] CHA BH,KIM JS,AHN JC,et al. The role of tauroursodeoxycholic acid on adipogenesis of human adipose-derived stem cells by modulation of ER stress[J]. Biomaterials,2014,35(9):2851-2858.
|
|
[12] Human Microbiome Project Consortium. Structure,function and diversity of the healthy human microbiome[J]. Nature,2012,486(7402):207-214.
|
|
[13] BRANDL K,SCHNABL B. Intestinal microbiota and nonalcoholic steatohepatitis[J]. Curr Opin Gastroenterol,2017,33(3):128-133.
|
|
[14] KOLODZIEJCZYK AA,ZHENG D,SHIBOLET O,et al. The role of the microbiome in NAFLD and NASH[J]. EMBO Mol Med,2019,11(2):e9302.
|
|
[15] SAFARI Z,GRARD P. The links between the gut microbiome and non-alcoholic fatty liver disease(NAFLD)[J]. Cell Mol Life Sci,2019,76(8):1541-1558.
|
|
[16] WAHLSTRM A,KOVATCHEVA-DATCHARY P,STHLMAN M,et al. Crosstalk between bile acids and gut microbiota and its impact on farnesoid X receptor signalling[J]. Dig Dis,2017,35(3):246-250.
|
|
[17] WAHLSTRM A,SAYIN SI,MARSCHALL HU,et al. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism[J]. Cell Metab,2016,24(1):41-50.
|
|
[18] CHENG S,ZHU L,FADEN HS. Interactions of bile acids and the gut microbiota:Learning from the differences in Clostridium difficile infection between children and adults[J]. Physiol Genomics,2019,51(6):218-223.
|
|
[19] FOUTS DE,TORRALBA M,NELSON KE,et al. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease[J]. J Hepatol,2012,56(6):1283-1292.
|
|
[20] DEVKOTA S,WANG Y,MUSCH MW,et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10–/–mice[J]. Nature,2012,487(7405):104-108.
|
|
[21] SUTTI S,BRUZZS,ALBANO E. The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis:A 2015 update[J].Expert Rev Gastroenterol Hepatol,2016,10(2):243-253.
|
|
[22] FIORUCCI S,BIAGIOLI M,ZAMPELLA A,et al. Bile acids activated receptors regulate innate immunity[J]. Front Immunol,2018,9:1853.
|
|
[23] BIAGIOLI M,CARINO A. Signaling from intestine to the host:How bile acids regulate intestinal and liver immunity[J].Handb Exp Pharmacol,2019,256:95-108.
|
|
[24] FEROLLA SM,ARMILIATO GN,COUTO CA,et al. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease[J]. Nutrients,2014,6(12):5583-5599.
|
|
[25] GUO C,XIE S,CHI Z,et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome[J]. Immunity,2016,45(4):802-816.
|
|
[26] RENGA B,MENCARELLI A,CIPRIANI S,et al. The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation[J]. PLo S One,2013,8(1):e54472.
|
|
[27] SONG X,SUN X,OH SF,et al. Microbial bile acid metabolites modulate gut RORγ+regulatory T cell homeostasis[J].Nature,2020,577(7790):410-415.
|
|
[28] JIANG C,XIE C,LI F,et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease[J]. J Clin Invest,2015,125(1):386-402.
|
|
[29] SAMUEL VT,SHULMAN GI. Mechanisms for insulin resistance:Common threads and missing links[J]. Cel,2012,148(5):852-871.
|
|
[30] CONTRERAS C,GONZLEZ-GARCA I,MARTNEZ-SNCHEZ N,et al. Central ceramide-induced hypothalamic lipotoxicity and ER stress regulate energy balance[J]. Cell Rep,2014,9(1):366-377.
|
|
[31] FANG S,SUH JM,REILLY SM,et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance[J]. Nat Med,2015,21(2):159-165.
|
|
[32] SCHMITT J,KONG B,STIEGER B,et al. Protective effects of farnesoid X receptor(FXR)on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15signal[J]. Liver Int,2015,35(4):1133-1144.
|
|
[33] LEE EA,LEE DI,KIM HY,et al. Cyp7a1 is continuously increased with disrupted Fxr-mediated feedback inhibition in hypercholesterolemic TALLYHO/Jng mice[J]. Biochem Biophys Acta Mol Cell Biol Lipids,2018,1863(1):20-25.
|
|
[34] NEUSCHWANDER-TETRI BA,LOOMBA R,SANYAL AJ,et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic,non-alcoholic steatohepatitis(FLINT):A multicentre,randomised,placebo-controlled trial[J]. Lancet,2015,385(9972):956-965.
|
|
[35] VASSILEVA G,HU W,HOOS L,et al. Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice[J]. J Endocrinol,2010,205(3):225-232.
|
|
[36] McMAHAN RH,WANG XX,CHENG LL,et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease[J]. J Biol Chem,2013,288(17):11761-11770.
|
|
[37] THOMAS C,GIOIELLO A,NORIEGA L,et al. TGR5-mediated bile acid sensing controls glucose homeostasis[J]. Cell Metab,2009,10(3):167-177.
|
|
[38] CHAI SC,CHERIAN MT,WANG YM,et al. Small-molecule modulators of PXR and CAR[J]. Biochim Biophys Acta,2016,1859(9):1141-1154.
|
|
[39] COPPLE BL,LI T. Pharmacology of bile acid receptors:Evolution of bile acids from simple detergents to complex signaling molecules[J]. Pharmacol Res,2016,104:9-21.
|
|
[40] STAUDINGER JL,GOODWIN B,JONES SA,et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity[J]. Proc Natl Acad Sci U S A,2001,98(6):3369-3374.
|
|
[41] LI X,WANG Z,KLAUNIG JE. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease[J]. Toxicology,2018,410:199-213.
|
|
[42] ZHANG X,MA Z,LIANG Q,et al. Tanshinone IIA exerts protective effects in a LCA-induced cholestatic liver model associated with participation of pregnane X receptor[J]. J Ethnopharmacol,2015,164:357-367.
|
|
[43] CHENG J,FANG ZZ,KIM JH,et al. Intestinal CYP3A4 protects against lithocholic acid-induced hepatotoxicity in intestine-specific VDR-deficient mice[J]. J Lipid Res,2014,55(3):455-465.
|
|
[44] DELLA CORTE C,CARPINO G,de VITO R,et al. Docosahexanoic acid plus vitamin D treatment improves features of NAFLD in children with serum vitamin D deficiency:Results from a single centre trial[J]. PLo S One,2016,11(12):e0168216.
|
|
[45] LORVAND AMIRI H,AGAH S,TOLOUEI AZAR J,et al. Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet:Randomized, controlled,double-blind trial[J]. Clin Nutr,2017,36(6):1490-1497.
|
DownLoad: